More on TLX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $10.10 |
|
|||
| Open | $10.10 | ||||
| 52 Wk High | $2.18 | ||||
| 52 Wk Low | $0.30 | ||||
| Day High | $10.10 | ||||
| Day Low | $10.10 | ||||
| P/E | N/A | ||||
| EPS | $-3.32 | ||||
| Volume | 670 | ||||
- H.C. Wainwright Reiterates Buy Rating on Telix Pharmaceuticals Ltd (TLX)
- Telix Pharmaceuticals Ltd (TLX:AU) (TLX) PT Raised to AUD24.40 at JPMorgan
- Telix publishes Phase 1 prostate cancer therapy study in Cancers journal
- TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
- Form 6-K Telix Pharmaceuticals For: Jun 30
- Telix Pharmaceuticals Limited (TLX) Reports Q2 results
- Telix Pharmaceuticals posts $247M in Q2 revenue, raises R&D outlook
- Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
- Telix doses first patient in Phase 3 kidney cancer drug trial
- Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
Entities mentioned with TLX
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- PDUFA | View Related Stories »
- Earnings | View Related Stories »
- Show More...
